Background Previous studies have shown an association between height and colorectal cancer (CRC). None of those studies adjusted the association for known risk factors, such as diabetes mellitus and chronic exposure to aspirin/ NSAIDs. Only two studies evaluated the risk among male individuals.
Introduction
BMI is a well-known anthropomorphic variable that has been shown in previous studies to be associated with increased colorectal cancer (CRC) incidence and outcome, more prominently in male than in female individuals [1] [2] [3] [4] . Similar to BMI and weight, height serves as a proxy for several genetic and environmental exposures in early life, such as socioeconomic status, energy intake, and growth factor levels, which may impact cancer risk later in life [5] [6] [7] [8] . The concentration of insulin-like growth factor-1 is associated with both growth during childhood and a higher risk for prostate, breast, and colorectal cancers [9] [10] [11] [12] . Likewise, energy restriction during childhood is associated with a lower CRC risk in adults [13, 14] . Additional mechanisms underlying the association between height and cancer risk are related to the larger number of cells in taller individuals, as expressed in terms of increased colonic length and skin surface area [15] .
Previous studies have evaluated the association of height with cancers in different anatomic sites and shown increased risks for melanoma, breast, ovarian, prostate, lung, and colorectal cancers, as well as elevated sitespecific mortality [16] [17] [18] [19] [20] [21] [22] . For CRC, sex, tumor site, and smoking status were evaluated as possible modifiers of the association, with conflicting results [16, 22] . Two previous studies, the Netherlands cohort study (NLCS) [23] and a large retrospective study from Norway [24] , evaluated the association of increasing height with CRC risk among male individuals, with conflicting results. In the first study, increasing height (per 5 cm) was not associated with increased CRC risk [hazard ratio (HR) 0.96, 95% confidence interval (CI) 0.8-1.04], whereas in the second study, an increase in height, both among male and female individuals, was associated with increased CRC risk [relative risk (RR) 1.14, 95% CI 1.11-1.16, and 1.17, 95% CI 1.14-1.20, respectively]. Two prospective studies among cohorts of women, the million women study in the UK and the Canadian national breast screening study, showed a lower HR for the association between height and CRC in women who were current smokers compared with never smokers [22, 25] . Several studies reported a higher risk for tumors located in the proximal colon among taller individuals [24, 26] , whereas other studies reported a higher risk for distal lesions [23] .
Importantly, none of the prior studies adjusted for important confounders to this association such as diabetes mellitus, ischemic heart disease, and chronic exposure to aspirin or NSAIDs [22, 25, 27] , and only one study adjusted for previous colorectal cancer screening [22] .
The goal of the current study was to evaluate the association between height and CRC in a large populationbased cohort while controlling for known risk factors of CRC.
Methods

Study design
We conducted a nested case-control study using The Health Improvement Network (THIN), a large population-based electronic medical record database from the UK. The study was approved by the Institutional Review Board at the University of Pennsylvania and by the Scientific Review Committee of THIN.
Data source
The THIN database contains comprehensive medical records of ∼ 10 million patients treated by general practitioners throughout the UK and is representative of the general UK population. All practices contributing data to THIN follow a standardized protocol of entering information and transmitting information to the central database. Each medical diagnosis is defined using Read diagnostic codes; each medication is uniquely coded using multiplex codes. Data quality is monitored through routine analysis of the entered data [28, 29] . Hundreds of epidemiologic studies have been performed using the THIN database, showing excellent quality of information on prescriptions and medical diagnoses [30] .
Study cohort
All patients receiving medical care from 1995 to 2013 from a THIN practitioner were potentially eligible for inclusion (Fig. 1) . Patients with a family history of CRC syndromes, inflammatory bowel disease, or prevalent CRC, as well as those without documented height before the index date, were excluded. Follow-up started at the later of either the date at which the THIN practice started using the electronic medical record Vision software or 183 days after the date at which the patient registered with their general practitioner, and it ended on the index date (defined below). Patients who were diagnosed with CRC within 183 days after initiation of the follow-up period were excluded to avoid prevalent cases [31] .
Case selection
Cases were defined as all individuals in the cohort who were given at least one medical Read code for CRC during the follow-up period and were older than 40 years at the time of diagnosis. Index date was defined as the date of first CRC diagnosis. Of note, a previous study demonstrated that the incidence of CRC in THIN was comparable to the incidence in the entire population of the UK, as reported in the cancer registry [32] .
Selection of controls
Selection of the control group was based on incidencedensity sampling [33] . The potentially eligible control pool for each patient comprised all individuals from the THIN database who remained at risk for CRC (i.e. who
had not yet developed CRC or undergone colectomy) on the calendar date at which the patient was first diagnosed with CRC. Up to four eligible controls were matched with each patient in terms of age (using age group categories of 5 years), sex, practice site, and both duration and calendar period of follow-up. Controls were assigned the same index date as their matched patient.
Exposures and covariates
The exposure of interest was height, measured in meters and defined on the basis of the last recorded measurement before the index date. We also examined a comprehensive list of potential confounders that are either known or suspected risk factors for CRC such as lifestyle parameters including BMI (< 25, 25-29, 30-39, > 40), smoking history (current, past, or never), alcohol consumption (any use and alcoholism/alcohol dependence), and previous colonoscopy (i.e. > 2 years before the index date); medical comorbidities (including diabetes mellitus, ischemic heart disease, and connective tissue diseases such as rheumatoid arthritis and systemic lupus erythematosus, all with initial diagnosis before the index date); and chronic use of aspirin/NSAIDs (first prescription at least 12 months before the index date, last prescription within 6 months before the index date, and cumulative duration of therapy > 365 days).
Statistical analysis
The baseline characteristics of patients and controls were compared using χ 2 -tests for categorical variables and t-tests for continuous variables. The primary analysis included multivariable conditional logistic regression to estimate the odds ratios (ORs) and 95% CIs for the association between CRC and height. In this analysis, height was entered into the model as a categorical variable, using quartiles of increasing height (< 1.7, 1.7-1.75, 1.75-1.79, > 1.79 in male individuals and < 1.56, 1.56-1.6, 1.6-1.65, > 1.65 in female individuals), and as a continuous variable (per 10-cm increase). The analysis was adjusted for all the confounders that were measured: BMI, alcohol consumption, smoking history, chronic NSAID use, diabetes mellitus, ischemic heart disease, connective tissue disease, and previous colonoscopies. In addition, the results were stratified according to sex, age (< 60 and > 60 years), and smoking status (current past or never) to assess for possible effect modifiers previously described in the literature. All calculations were performed using STATA 13 (Statacorp LP, College Station, Texas, USA).
Results
The study included 9978 CRC patients and 26 847 matched controls (Fig. 1) . The characteristics of the patients and controls are shown in Table 1 . As expected, patients were more likely to have a medical history of diabetes mellitus (17.3 vs. 15%), BMI above 40 (3.2 vs. 2.6%), and a history of ever smoking or alcoholism, and they were less likely to be chronic users of aspirin/NSAID. Of note, the prevalence of presumed screening colonoscopy in the study population was low (2.0% of patients and 2.7% of controls; Table 1 ).
For both men and women, univariate analysis demonstrated a significant increase in CRC risk associated with height, both as a continuous variable and by quartiles ( Table 2 ). The effect estimates were generally unchanged in the multivariable analysis ( Table 2 ). The adjusted OR for CRC when comparing the highest height quartile with the lowest height quartile was 1.25 (95% CI 1.14-1.37) for male and 1.25 (95% CI 1.12-1.39) for female individuals. The adjusted ORs for CRC associated for every 10-cm increase in height was modestly higher for female (OR 1.16, 95% CI 1.10-1.23) compared with male (OR 1.10, 95% CI: 1.05-1.15) individuals (Table 2) .
We further evaluated whether the association between CRC risk and height varied by age (i.e. > 60 and < 60 years). The association between height and CRC risk was slightly more pronounced among men over 60 years compared with those younger than 60 years (OR 1.11 vs. 1.05). However, there was no statistically significant interaction by age group (Table 3) . Among women, the association between height and CRC was similar between the two age groups (Table 4 ).
Discussion
The current population-based nested case-control study demonstrated that increasing height is associated with an elevated CRC risk. The effect of height on CRC risk was similar in both men and women of different age groups (i.e. > 60 and <60 years), as well as when analyzed as a continuous or categorical variable. Unique aspects of the present work include matching cases and controls in terms of practice site and duration of follow-up and adjusting for potential confounders such as diabetes mellitus, BMI, smoking, alcoholism, chronic aspirin/ NSAID use, and previous screening colonoscopies. The association between height and CRC was independent of these known cancer risk factors, and adjustment did not change the crude OR.
The association between height and cancer risk has been examined in a limited number of studies. Prior studies have evaluated overall cancer risk and were thus unable to adjust for CRC-specific risk factors. One cohort study from the Netherlands (NLCS) focused on CRC; however, it adjusted only for smoking, alcohol use, education level, and physical activity and relied upon self-reported height and weight data, which may be prone to misclassification or recall bias. A major strength of THIN, the data source used in this study, is that height data are prospectively recorded and less likely to be impacted by recall or self-report bias.
In contrast to the results from the NLCS, which showed an increase in CRC risk only among women, our work showed similar risks in both men and women. We found that the OR among male individuals appeared to be lower among younger versus older male individuals. This difference associated with age might provide a possible explanation for the inconsistency of our results compared with the NLCS, as the mean age for male individuals in the NLCS was 61 years compared with 71 years in the current work. Our study had several limitations. The THIN database lacks information on premalignant adenomas, tumor location, and tumor stage. Previous work reported conflicting results on the influence of tumor location on the association between height and CRC risk. Although some studies show a higher association with colon compared with rectal cancers [26] , others reported a higher risk for distal compared with proximal colonic lesions [13] . We were unable to evaluate this possible association in the current study due to lack of information. Considering other potential limitations, our study suffered from missing data. For example, information on height was missing for 11 012 cases; thus, the analysis was restricted to participants with height information. However, there is no reason to assume differential recording of height on the basis of height or CRC status. The THIN database also lack information on other known CRC risk factors such as diet composition and physical activity. Finally, the current work did not evaluate any specific biological mechanism that could explain the elevated risk, although several biologically plausible pathways have been described previously.
In summary, we have shown that increasing height is an independent risk factor for CRC in both men and women. Major risk scores for CRC currently do not include height as part of their nomogram [34] , and only one model in the Korean population includes height as a risk factor among women [35] . If confirmed, height should be included in future risk score models for both sexes. Adjusted to diabetes mellitus, ischemic heart disease, connective tissue diseases, BMI, smoking history, alcohol consumption, chronic use of aspirin/NSAIDs, and performance of screening colonoscopies. Adjusted to diabetes mellitus, ischemic heart disease, connective tissue diseases, BMI, smoking history, alcohol consumption, chronic use of aspirin/NSAIDs, and performance of screening colonoscopies.
